Ryan M. Carr

GI Medical Oncologist | Cancer Biologist
"Nothing in biology makes sense except in the light of evolution"
@MayoClinic @MayoCancerCare

[Thor Halfdanarson @OncoThor]

As expected, @RMCarrLab delivered a brilliant presentation on the use of molecular testing in clinical practice. If you need a speaker on that topic, he's the one you should contact...

Super practical review of the basics of testing, the anatomy of the genomics report and the interpretation so it can be applied to practice.

@MayoCancerCare @MayoMedEd @MayoHemeOnc

[Ryan M. Carr @RMCarrLab]

Issue #2 of the Mayo Pancreatic Cancer Working Group Newsletter is Live. The RAS era becomes very real, early detection gets more concrete, and the stroma still refuses to be simple

https://t.co/UtfDIlKYNy

[Ryan M. Carr @RMCarrLab]

Productive #AACRpan25. Strong showing from @MayoCancerCare and our lab across computational pathology, epigenetics, and mouse models, aimed at practical gains in PDAC care. Back to work. #PancreaticCancer #PDAC #CancerResearch #TranslationalResearch

[Ryan M. Carr @RMCarrLab]

5/ Clinically: for fit pts, modified FFX remains common; CRT is a valid alternative when FFX is intolerable/contraindicated. True “best” regimen awaits A021806/PREOPANC-3. Personalize the neoadjuvant plan.

#PersonalizedOncology #AdaptedTherapy #ResponseAdaptive

[Ryan M. Carr @RMCarrLab]

1/ PREOPANC-2 (resectable/borderline PDAC): no OS advantage for neoadjuvant FOLFIRINOX vs gemcitabine-CRT→surgery→adjuvant gemcitabine. mOS 21.9 vs 21.3 mo (HR 0.88; p=0.32). Both are reasonable options.

#PREOPANC2 #PancreasCancerResearch #ClinicalTrials #TrialTwitter

[Ryan M. Carr @RMCarrLab]

4/ Key limit to generalizability: the trial was not response-adaptive. Restaging occurred after 4 and 8 FFX cycles, and treatment stopped for progression/toxicity, but there was no protocolized switch for poor responders (e.g., to CRT/alt chemo).

[Saurabh Zanwar @ZanwarSaurabh]

Woah! Can’t even remember how long back this was! Lot of the #mayocrew still here!
@UDuraniMD @hampel_p #moritzbinder
@JithmaA

@RMCarrLab has defected to the solid tumour world and I am sure @E_D_Bezerra isn’t complaining about the weather anymore!

#ASH24

[Aakash Desai @ADesaiMD]

🚀In our latest 📜we explored the molecular characteristics of #KRAS wt #PDAC and found actionable genetic variants.
➡️TFG-MET rearrangement showed response to a c-MET inhibitor.
Precision medicine #futureisnow! 🔬 @RMCarrLab @AMansfieldMD @GIcancerDoc https://t.co/QMzuZ6arDs

[Ryan M. Carr @RMCarrLab]

Transcriptomic analysis of a cohort of KRAS wildtype PDAC reveals enrichment of KRAS signaling in a significant subset. KRAS (on) inhibitors may have utility in these patients.

https://t.co/D4A9cFlDnC #mdpicancers via @Cancers_MDPI

[Ryan M. Carr @RMCarrLab]

Always enjoy @dbasanta presenting on math modeling of cancer. This time, models evolvability.

#CancerEvoEco24

[Ryan M. Carr @RMCarrLab]

Thought provoking presentation from @mariasecrier on cell intrinsic and microenvironmental constraints of EMT.

#CancerEvoEco24

[Ryan M. Carr @RMCarrLab]

Beautiful work from @LauraMachesky demonstrating the effect of mechanosensing and other unique biophysical properties on pancreatic cancer cell metabolic plasticity.

#CancerEvoEco24

[Ryan M. Carr @RMCarrLab]

Learn more at https://t.co/WQbf9H3XiH
NCT05726864

Would you like to participate? Contact us:

Dr. Ryan Carr at: carr dot ryan at https://t.co/MS0mW5pYI6

Preston Buechler at: [phone] or buechler dot preston at https://t.co/MS0mW5pYI6

[Ryan M. Carr @RMCarrLab]

Please consider supporting my awesome colleague, Elise Novo and her family during this challenging time.
https://t.co/8TfSA3WSW9

[Jeffrey West @mathoncbro]

Moffitt's best differentiator is the ability to work on math models w/ clinical translational potential:
https://t.co/3QPGmneFug

mathematical models as part of the decision-making process within a tumor board -- an "evolutionary tumor board:

https://t.co/EaGiu3Yj3I

[Ryan M. Carr @RMCarrLab]

An informative and inspirational workshop. Thank you @theNASEM

[National Academies @theNASEM]

Digital twin technologies have the potential to revolutionize biomedical research, from personalized medicine to pharmaceutical development.

Join us January 30 to learn more about #DigitalTwins and their development and use in #biomedicine: https://t.co/ooM4a97mW0

[Ricard Solé @ricard_sole]

Is biological complexity predictable? Can genes explain development? No, due to the emergent nature of the genotype-phenotype map: higher-level properties are irreducible to lower-level ones. Here's my drawing with CH Waddington as a demon. @manlius84 @sanewman1 @drmichaellevin

[Ryan M. Carr @RMCarrLab]

Getting festive! @ Mayo Clinic Rochester MN https://t.co/suH0uraE1l